Abstract
dc:descriptionBackground - Objective: GM-CSF can mobilize peripheral blood progenitors, prevent or reverse hematopoietic cell toxicity, augment their pro-inflammatory response, reverse monocyte deactivation observed in sepsis and control infection. The aim of the study was to investigate the effects of molgramostim administration in patients with severe sepsis. Methods: In this prospective uncontrolled clinical study, 20 critically ill patients with severe sepsis were given molgramostim 300 μg q12h sc for 3 days. Treatment for underlying disease and severe sepsis was also administered as medically indicated. Results: No adverse events were considered as drug-related. Temperature (p = 0.334) and PaO2/FiO2 index (p = 0.178) were not significantly changed. Total leukocyte and neutrophil count significantly increased (p < 0.001) during drug administration. SAPS II score was not significantly increased (p = 0.955) but there was a statistically significant decrease (p = 0.006) in SOFA score. Death probability on admission was not statistically different compared to mortality rate on day 28 and overall mortality (p = 0.238 and 0.700 respectively). There was a statistically significant decrease (p < 0.01) in serum TNF- a, TNF-RII and IL-2 and increase in TNF-RI levels between study entry and day 3. Mean ICU stay was 40.2±7.7 days. Conclusions: Molgramostim administration may not affect the PaO2/FiO2 index, may decrease SOFA score but does not produce significant clinical benefit in terms of outcome compared to death probability. It may also influence TNF-α, TNF-RI and TNF-RII serum complex levels. These changes may be attributed to the natural clinical course of sepsis or therapy applied.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2002
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Karabatsos, Elias
- Καραμπάτσος, Ηλίας
Subjects
dc:subject × 16Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/21565